Key Points
- Director Lewis Titterton, Jr. bought 10,000 Anixa Biosciences shares at $2.73 each, investing $27,300 and increasing his ownership to 996,967 shares.
- Anixa shares opened at $2.80, with a market capitalization of approximately $97.3 million. The company reported a quarterly loss of $0.08 per share, in line with analyst expectations.
- Analyst sentiment is mixed: three analysts rate the stock a Buy, while others rate it Hold or Sell. The consensus rating is Hold, with an average price target of $10.00.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) Director Lewis Titterton, Jr. bought 10,000 shares of Anixa Biosciences stock in a transaction dated Thursday, September 10th. The stock was acquired at an average cost of $2.73 per share, with a total value of $27,300.00. Following the completion of the acquisition, the director owned 996,967 shares of the company's stock, valued at $2,721,719.91. This represents a 1.01% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Anixa Biosciences Trading Up 1.4%
Shares of ANIX opened at $2.80 on Tuesday. The stock has a 50 day moving average of $3.33 and a 200 day moving average of $2.98. The company has a market capitalization of $97.34 million, a price-to-earnings ratio of -8.75 and a beta of 0.51. Anixa Biosciences Inc has a 12 month low of $2.32 and a 12 month high of $5.46.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). As a group, equities research analysts predict that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on ANIX shares. Zacks Research downgraded shares of Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. D. Boral Capital reiterated a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Wall Street Zen raised shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, June 20th. Citigroup restated a "buy" rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Anixa Biosciences in a report on Friday, June 12th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $10.00.
View Our Latest Analysis on Anixa Biosciences
Institutional Investors Weigh In On Anixa Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Anixa Biosciences during the second quarter valued at about $559,000. Bank of New York Mellon Corp purchased a new position in shares of Anixa Biosciences in the second quarter worth about $133,000. AXQ Capital LP purchased a new position in shares of Anixa Biosciences in the second quarter worth about $41,000. Corient Private Wealth LP bought a new stake in shares of Anixa Biosciences in the second quarter valued at approximately $105,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Anixa Biosciences in the second quarter valued at approximately $38,000. 29.13% of the stock is currently owned by institutional investors.
Anixa Biosciences Company Profile
(
Get Free Report)
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
